9 completed, 5 terminated, 3 unknown, 2 recruiting. 13 Phase 2, 4 Phase 3, 3 Phase 1, 2 Not applicable.
Follow Carcinoma, Small Cell Lung: new trials by email Literature Review of Carcinoma, Small Cell Lung trials Research Report on Carcinoma, Small Cell Lung
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer PF-08634404, Chemotherapy - Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Pfizer | 40 | 2026-07-02 | 2026-10-09 |
| Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients Tarlatamab - Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung | Phase 2 | Recruiting | Fundación GECP | 37 | 2026-05-20 | 2026-07-08 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide - Carcinoma, Small Cell Lung | Phase 3 | Active not recruiting | EpicentRx, Inc. | 292 | 2022-08-01 | 2024-10-31 |
| A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer Atezolizumab, Tiragolumab, Placebo - Carcinoma, Small Cell Lung | Phase 2 | Terminated | Hoffmann-La Roche | 24 | 2021-12-01 | 2023-10-23 |
| Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer Atezolizumab, Cisplatin, Carboplatin - Carcinoma, Small Cell Lung | Phase 2 | Completed | Hoffmann-La Roche | 56 | 2020-12-16 | 2024-07-29 |
| Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. PM 01183, Atezolizumab - Carcinoma, Small Cell Lung | Phase 1 / Phase 2 | Unknown | Fundacion Oncosur | 184 | 2019-12-13 | 2023-11-18 |
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer Neoantigen loaded DC vaccine - Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | Phase 1 | Unknown | Shenzhen People's Hospital | 30 | 2019-04-01 | 2019-03-12 |
| RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide - Carcinoma, Small Cell Lung | Phase 3 | Terminated | EpicentRx, Inc. | 18 | 2018-12-24 | 2024-03-26 |
| BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Nivolumab, Ipilimumab - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Completed | Lung Cancer Group Cologne | 90 | 2017-04-13 | 2024-01-17 |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers PEN-221 - Neuroendocrine Tumors, Carcinoma, Small Cell Lung | Phase 1 / Phase 2 | Completed | Tarveda Therapeutics | 89 | 2016-12-08 | 2021-12-14 |
| HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer HS-WBRT PCI, Conventional PCI - Carcinoma, Small Cell Lung | Not applicable | Unknown | General Hospital of Ningxia Medical University | 3 | 2016-03-01 | 2016-04-13 |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies AZD6244, MK-2206, Lapatinib - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Completed | National Cancer Institute (NCI) | 647 | 2011-02-08 | 2024-10-01 |
| N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy N-Acetylcysteine, Placebo - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Not applicable | Terminated | Rijnstate Hospital | 69 | 2008-03-01 | 2022-08-25 |
| Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma Glufosfamide - Carcinoma, Small Cell Lung | Phase 2 | Terminated | Threshold Pharmaceuticals | 50 | 2007-02-01 | 2009-04-30 |
| Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer irinotecan, carboplatin, bevacizumab - Carcinoma, Small Cell Lung, Lung Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 55 | 2006-03-01 | 2010-06-22 |
| Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer irinotecan, carboplatin, bevacizumab - Carcinoma, Small Cell Lung | Phase 2 | Completed | SCRI Development Innovations, LLC | 50 | 2006-02-01 | 2010-06-28 |
| Metabolomic Analysis of Lung Cancer 13-C-glucose - Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | Completed | University of Louisville | 249 | 2005-12-01 | 2022-05-09 | |
| Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer zoledronic acid - Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Terminated | University of Louisville | 28 | 2005-02-01 | 2018-03-05 |
Showing 20 of 22. Sign in to see all of them.
Small Cell Lung Carcinoma (22) · Carcinoma, Non-Small-Cell Lung (8) · Lung Neoplasms (7) · Breast Neoplasms (2) · Carcinoma, Neuroendocrine (2) · Esophageal Neoplasms (2) · Mesothelioma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Thymoma (2) · Anemia (1) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Carcinoma (1) · Carcinoma, Ductal (1)
Bronchial Neoplasms (22) · Carcinoma, Bronchogenic (22) · Lung Diseases (22) · Neoplasms by Site (22) · Respiratory Tract Diseases (22) · Neoplasms (21) · Respiratory Tract Neoplasms (21) · Thoracic Neoplasms (21) · Lung Neoplasms (15) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (4) · Hemic and Lymphatic Diseases (3) · Lymphatic Diseases (3) · Adenocarcinoma (2) · Adenoma (2)
Carboplatin (5) · Cisplatin (3) · Etoposide (3) · atezolizumab (3) · Bevacizumab (2) · Irinotecan (2) · PM 01183 (2) · RRx-001 (2) · 1,2-O-isopropylidene-D-glucofuranose (1) · AZD 6244 (1) · Acetylcysteine (1) · Drug Therapy (1) · Epoetin Alfa (1) · Erlotinib Hydrochloride (1) · Ipilimumab (1)
EpicentRx, Inc. (2) · Hoffmann-La Roche (2) · SCRI Development Innovations, LLC (2) · University of Louisville (2) · Eli Lilly and Company (1) · Fundacion Oncosur (1) · Fundación GECP (1) · General Hospital of Ningxia Medical University (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Lung Cancer Group Cologne (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · Rijnstate Hospital (1) · Shenzhen People's Hospital (1) · Tarveda Therapeutics (1)
United States (10) · China (5) · Spain (3) · Australia (1) · Brazil (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · South Korea (1) · Taiwan (1)
David R. Spigel, MD (2) · Arun Rajan, M.D. (1) · Bryan Oronsky, MD, PhD (1) · Donald M Miller, MD, PhD (1) · Gerold Bepler, MD, PhD (1) · Goetz H Kloecker, MD, MSPH (1) · Hye Ryun Kim (1) · Idris Bahce, MD (1) · John C Ruckdeschel, MD (1) · Lili Ren, Ph.D. (1) · Mariano Provencio, MD (1)
PMID 19875975, PMID 19901100, PMID 25667274, PMID 26028668, PMID 31509028, PMID 36920652, PMID 38964333
2016 (1), 2025 (1)